Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL963162 | 0.98 | ALDH1A1 (0.54) | SIGMAR1ALDH1A1CHRM5CHRM3DRD2 | |
| Piperazine SCHEMBL28845954 | 0.98 | SIGMAR1 (0.54) | SIGMAR1ALDH1A1CHRM5CHRM3DRD2 | |
| Hydrochloric Acid SCHEMBL17271878 | 0.98 | ALDH1A1 (0.54) | SIGMAR1ALDH1A1CHRM5CHRM3DRD2 | |
| SCHEMBL2011012 | 0.93 | SIGMAR1 (0.64) | SIGMAR1ALDH1A1CHRM5CHRM3DRD2 | |
| Hydrochloric Acid SCHEMBL2009563 | 0.91 | SIGMAR1 (0.62) | SIGMAR1ALDH1A1CHRM5CHRM3DRD2 | |
| Trifluoroacetic Acid SCHEMBL21816637 | 0.88 | SIGMAR1 (0.47) | SIGMAR1ALDH1A1CHRM5CHRM3DRD2 | |
| SCHEMBL9470969 | 0.84 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1CHRM5CHRM3MEN1 | |
| SCHEMBL8393969 | 0.84 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1CHRM5CHRM3MEN1 | |
| SCHEMBL665674 | 0.82 | SIGMAR1 (0.61) | SIGMAR1ALDH1A1CHRM5CHRM3MEN1 | |
| SCHEMBL2010851 | 0.82 | CHRM5 (0.54) | SIGMAR1ALDH1A1CHRM5CHRM3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109503573-A | 2- substituted anilinic pyrimidine derivatives and application thereof | 昆明圣加南生物科技有限公司 | 2019-03-22 | — | — | CN | claimed |
| CN-105348266-B | 3 chlorine N [3 (the base amino of the pyrimidine 2) phenyl] propionamides or its salt of substitution | 阿斯利康(瑞典)有限公司 | 2018-04-10 | — | — | CN | claimed |
| CN-105175396-B | 4 methoxyl group N of substitution3The diamine compound of (base of pyrimidine 2) benzene 1,3 and its salt | 阿斯利康(瑞典)有限公司 | 2018-01-16 | — | — | CN | claimed |
| CN-105254616-B | The substituted amines of N (nitrobenzophenone of 2 methoxyl group 5) pyrimidine 2 and its salt | 阿斯利康(瑞典)有限公司 | 2017-10-17 | — | — | CN | claimed |
| EP-1831206-B1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARM INC (US) | 2011-08-24 | — | — | EP | claimed |
| EP-2044036-B1 | [4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2011-05-04 | — | — | EP | claimed |
| JP-2008521903-A | — | — | 2008-06-26 | — | — | JP | claimed |
| EP-1831206-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006060381-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | claimed |
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-12-26 | — | — | US | disclosed |
| EP-4050005-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2002085885-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | disclosed |
| EP-0551993-B1 | Pyrrolidine derivatives and process for preparing the same | SUMITOMO PHARMA (JP) | 1996-07-10 | — | — | EP | disclosed |
| US-5322952-A | Pyrrolidine derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-06-21 | — | — | US | disclosed |
| EP-0551993-A1 | Pyrrolidine derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | SIGMAR1 3480/4885ALDH1A1 205/4885CHRM5 3960/4885 |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | SIGMAR1 2832/4885ALDH1A1 2153/4885CHRM5 2848/4885 |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | SIGMAR1 3480/4885ALDH1A1 205/4885CHRM5 3960/4885 |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | KIT, CHUK, TNNI3K | SIGMAR1 3147/4885ALDH1A1 977/4885CHRM5 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.